Red Hair and Drug Metabolism: Current Evidence
There is insufficient evidence to support that red hair phenotype alone significantly alters drug metabolism in clinical practice, and routine adjustment of drug dosing based solely on hair color is not warranted.
The Biological Hypothesis
Red hair is associated with variants in the melanocortin-1 receptor (MC1R) gene. Some researchers have hypothesized that these genetic variants might influence pain sensitivity and drug responses, particularly to analgesics and anesthetics 1. However, the clinical significance of this association remains unclear and controversial.
Evidence for Anesthetic Agents
For propofol, a commonly used IV anesthetic, red hair phenotype does not affect pharmacokinetics or pharmacodynamics 2. A well-designed study comparing red-haired and dark-haired volunteers found no difference in the propofol concentration needed to achieve half-maximal electroencephalogram response (Ce50 BIS: 2.57 μg/mL vs 2.71 μg/mL, respectively). This indicates that redheads do not require different propofol dosing for anesthesia.
Evidence for Opioid Metabolism
The relationship between red hair and opioid metabolism is more complex but ultimately not clinically actionable based on hair color alone:
CYP2D6 Polymorphisms Matter More Than Hair Color
- CYP2D6 genetic variants, not hair color, are the critical determinants of opioid metabolism 3, 4
- CYP2D6 metabolizes several opioids including codeine, tramadol, hydrocodone, and oxycodone
- CYP2D6 polymorphisms vary by ethnicity (more common in Asians for poor metabolizers) but are not specifically linked to red hair phenotype 5
Clinical Guidelines Focus on CYP2D6 Testing, Not Hair Color
Current NCCN (2025) and CPIC guidelines recommend:
- Avoid codeine and tramadol in CYP2D6 ultrarapid metabolizers (risk of toxicity) 3
- Avoid codeine and tramadol in CYP2D6 poor metabolizers (lack of analgesic effect) 3
- Consider pharmacogenomic testing when concerns of toxicity or lack of response exist 3
- However, there is insufficient evidence to recommend routine genetic testing, including for CYP2D6, to guide opioid dosing 5
The Inconclusive Nature of Red Hair Research
A 2024 narrative review examining red hair and drug responsiveness concluded that results are inconclusive 1. While some studies suggest altered pain sensitivity in red-haired individuals (particularly women), the data are contradictory:
- Some evidence shows increased pain sensitivity in red-haired women
- Other data indicate higher pain tolerance in homozygous MC1R variant carriers
- Varied responses to analgesia have been reported in both directions
- Studies attempting to link red hair to altered hypnotic requirements have failed to find consistent associations
Clinical Approach
Base drug selection and dosing on established pharmacogenetic markers (like CYP2D6 status when available), not on hair color:
For opioid selection: Choose based on patient-specific factors including renal function, prior opioid exposure, and known drug interactions 3
If CYP2D6 status is known:
For anesthetics: Dose propofol based on body weight and clinical response, not hair color 2
When pharmacogenetic testing is considered: Consult a clinical pharmacist or pharmacogenomics specialist for interpretation 3
Key Pitfalls to Avoid
- Do not adjust drug dosing based solely on red hair phenotype - this is not supported by current evidence or guidelines
- Do not assume all redheads are CYP2D6 poor metabolizers - MC1R variants and CYP2D6 variants are separate genetic phenomena
- Do not order routine CYP2D6 testing for all patients - current guidelines indicate insufficient evidence for routine use 5
- Be aware that CYP2D6 polymorphisms exhibit substrate-specific differences 6, meaning the same genetic variant may affect different drugs differently